Stealth BioTherapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference on December 3, 2014

Piper Jaffray Healthcare Conference 2014

NEWTON, Mass.--()--Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company committed to bringing therapies that target mitochondrial dysfunction to patients with severe acute and chronic diseases, today announced that Travis Wilson, Chief Executive Officer, is presenting a corporate overview at Piper Jaffray’s 26th Annual Healthcare Conference.

The presentation will take place on Wednesday, December 3, 2014 at 10:50 a.m. EST at The New York Palace Hotel in New York, NY.

About Stealth BioTherapeutics

Stealth BioTherapeutics is a privately-held biopharmaceutical company committed to bringing mitochondria-targeted therapeutics to patients to treat both common and rare diseases. As the key common element in a variety of serious, debilitating diseases, mitochondria - the cell’s energy source - offer a promising yet untapped therapeutic target for diseases with significant unmet treatment needs. Stealth is developing its lead compounds Bendavia™ and Ocuvia™ in multiple therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases, and defining the broad potential of mitochondria-targeted therapies. Stealth’s promising pipeline of preclinical and clinical compounds is supported by more than 100 independent, peer-reviewed publications, abstracts and presentations.

Contacts

Media Relations
dna communications
Taylor Ramsey, 617-520-7018
Tramsey@WeberShandwick.com
or
Investor Relations
Stern IR
Beth DelGiacco, 212-362-1200
Beth@sternir.com

Contacts

Media Relations
dna communications
Taylor Ramsey, 617-520-7018
Tramsey@WeberShandwick.com
or
Investor Relations
Stern IR
Beth DelGiacco, 212-362-1200
Beth@sternir.com